Compare PROF & DMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROF | DMB |
|---|---|---|
| Founded | N/A | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.8M | 203.6M |
| IPO Year | 2017 | N/A |
| Metric | PROF | DMB |
|---|---|---|
| Price | $5.68 | $9.89 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 120.7K | 45.3K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.17% |
| EPS Growth | ★ 25.89 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,098,000.00 | N/A |
| Revenue This Year | $92.40 | N/A |
| Revenue Next Year | $64.10 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 50.73 | N/A |
| 52 Week Low | $3.92 | $10.14 |
| 52 Week High | $8.95 | $11.28 |
| Indicator | PROF | DMB |
|---|---|---|
| Relative Strength Index (RSI) | 27.52 | 21.54 |
| Support Level | $4.97 | N/A |
| Resistance Level | $6.06 | $11.19 |
| Average True Range (ATR) | 0.35 | 0.10 |
| MACD | -0.10 | -0.04 |
| Stochastic Oscillator | 16.23 | 1.68 |
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
BNY Mellon Municipal Bond Infrastructure Fund, Inc. is a diversified closed-end management investment company. The fund's investment objective is to provide as high a current income exempt from regular federal income tax as is consistent with the preservation of capital. It invests in transportation, energy and utilities, social infrastructure, and water and environmental sectors.